This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mortimer J. Lacher, MD; William Geller, MD

JAMA. 1966;195(6):486-488.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN PREGNANT PATIENTS with Hodgkin's disease it is occasionally necessary to use various chemotherapeutic agents and to accept the possible risk of a teratogenic effect on the fetus. In most cases, however, potentially teratogenic agents have failed to produce deleterious effects on the human fetus when administered during and after the first trimester of pregnancy.^1,2 In a few instances in humans, alkylating agents given during the first trimester of pregnancy have been associated with fetal anomalies.^2,3

As more and more cases of pregnant patients with Hodgkin's disease who have received chemotherapy during pregnancy become known, the risk of such treatment may be diminished merely by the weight of empirical evidence against any serious effect on the fetus. With this in mind Sokol and Lessmann,¹ Shirkey,⁴ and Lacher⁵ have stressed the equal importance of reporting normal data as well as anomalies.

The following report illustrates the . . . [Full Text PDF of this Article]

Author Affiliations
From the Medical Oncology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases and the James Ewing Hospital of the City of New York.

Footnotes
Reprint requests to 444 E 68th St, New York 10021 (Dr. Lacher).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?